Anti Inflammatory News and Research

RSS

Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced financial results for the quarter ended March 31, 2010. The Company also highlighted recent achievements.

14 May 2010

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare, Inc. today announced progress on Fiscal 2010 Initiatives and financial results for the Quarter ending March 31, 2010.

13 May 2010

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

PLx Pharma, a pharmaceutical company developing safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs), today announced that it has been awarded multiple grants from the National Institutes of Health (NIH) totaling approximately $2,000,000. This funding has been awarded to support further advancement of a range of products currently under development by PLx.

12 May 2010

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Drug-releasing stents are more effective than bare metal stents at keeping a blocked artery open after angioplasty, but the difference does not result in fewer deaths or subsequent heart attacks after the procedure, according to a review of recent studies.

12 May 2010

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.

12 May 2010

ProBioGen signs contract with Virdante Biopharmaceuticals

ProBioGen AG, a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company.

12 May 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.

11 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Study reveals benefits of X-ray guided steroid injections for treatment of hamstring tendonitis

Fluoroscopic (X-ray) guided steroid injections offer a safe and effective alternative to the conventional treatment of hamstring tendonitis, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA. Conventional treatment includes rest, anti-inflammatory drugs, and physical therapy.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

New combination eye drops effective in treating bacterial keratitis

Scientists are reporting development of a potential new way of enabling patients with bacterial keratitis to stick with the extraordinarily intensive treatment needed for this potentially blinding eye infection.

6 May 2010

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

6 May 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.

6 May 2010

Anti Inflammatory News and Research

Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010

Stereotaxis to be featured prominently in 31st HRS

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

ProBioGen signs contract with Virdante Biopharmaceuticals

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Study reveals benefits of X-ray guided steroid injections for treatment of hamstring tendonitis

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

New combination eye drops effective in treating bacterial keratitis

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News